Tempus AI

Tempus AI's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing

Tempus AI's IPS Biomarker Validation: A Catalyst for Precision Oncology Diagnostics?

Tempus AI Advances Hereditary Cancer Testing and Immunotherapy Prediction, Despite Share Price Decline

Bullish Thesis on Tempus AI: A High-Growth Healthcare Stock with Robust Competitive Advantage

Tempus AI Director Epstein David R sells 370 shares at $59.41 on 2026-02-02.

Catalyst<ul> <li>Most analysts rate TEM Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (6 bearish vs 0 bullish).</li> <li>Fund flows are negative across Small, Medium, and Extra-large buckets, indicating investor withdrawal.</li></ul>

Key Factors

Tempus AI (TEM) shares closed up 4.71% on February 6, 2026, driven by analyst upgrades and renewed investor confidence despite a 23.51% drop in trading volume.Tempus AI (TEM) shares fell 2.07% on February 5, 2026, with $460M in trading volume, reflecting mixed sentiment amid broader healthcare AI sector volatility.Tempus AI's Immune Profile Score (IPS) was clinically validated to more accurately predict immunotherapy outcomes than conventional biomarkers, advancing its precision oncology diagnostics platform.Tempus AI (TEM) reported Q4 revenue of $334.2 million, a 84.7% year-over-year increase, with gross profit surging 98.4% to $209.9 million, demonstrating significant operating leverage.Tempus AI (TEM) insider Epstein David R sold 370 shares at $59.41 per share on February 2, 2026, as part of a recent insider transaction.

TEM News